Recipharm, a contract development and manufacturing organization (CDMO), recently announced its new partnership with Swedish CRO Clinical Trial Consultants (CTC) for the development of a comprehensive list of services for first-in-human clinical trials. The partnership’s project, titled Recipharm Pathway to Clinic, is geared toward streamlining clinical trials and facilitating research from the early phase of formulation development to trial implementation.
Amylon spinoff marks positive CNS trend
ProQR Therapeutics recently spun out Amylon Therapeutics, a privately held company focused on the development of therapies for central nervous system (CNS) disorders. The CNS field holds much promise, despite some research challenges. Amylon will specifically focus on developing therapeutics for beta amyloid-related disorders. The spinoff will continue research and work on the development of therapies for CNS disorders.
To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.